Stocks Tumble On Tetraphase, Flexion Failures; Surge On Akebia Win
This article was originally published in Scrip
Executive Summary
Antibiotic developer Tetraphase Pharmaceuticals Inc. and arthritis pain drug maker Flexion Therapeutics Inc. were battered in after-hours trading on Sept. 8 after the companies said their lead drug candidates failed to reach statistical significance in late-stage clinical trials, but investors rewarded Akebia Therapeutics Inc. for positive mid-stage results for its anemia drug after the stock market closed.
You may also be interested in...
Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms
Tetraphase has been keeping its head down since a 2015 Phase III trial failure for its lead antibiotic drug eravacycline sliced around $1.3bn from the company's market cap – but 2017 will be a turnaround year, says CEO Guy Macdonald.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.